J&J Slammed With Costliest Talc Verdict Yet; California Plaintiff Awarded $417M
This article was originally published in The Rose Sheet
Executive Summary
California could emerge as the new hub for talc litigation following a Los Angeles jury verdict awarding $417m in damages to a terminally ill plaintiff who linked her ovarian cancer to longtime use of J&J's talcum powder products.
You may also be interested in...
J&J’s Talc Winning Streak Continues With Calif. Mesothelioma Verdict
A California jury sided with J&J Nov. 16 in the first trial over whether alleged asbestos in the firm's talcum powders caused plaintiff's mesothelioma. The verdict could help check what threatens to be a new field of litigation against J&J for alleged talc dangers, and the firm also is gaining momentum in its defense against ovarian cancer claims.
Product Liability Litigation Playbook: Pros And Cons For Pharma
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.
J&J May Have Just Received Lifeline Out Of St. Louis Talc Tort Morass
A judge in the Missouri state court where J&J has suffered a series of hefty losses declared a mistrial June 19 in the latest talc-cancer case to be heard by jurors. The decision came two days after a US Supreme Court decision that also could trigger reversals of costly J&J verdicts currently under appeal.